{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:53:49Z","timestamp":1793393629312,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"14","license":[{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000053","name":"U.S. Department of Health & Human Services | NIH | National Eye Institute","doi-asserted-by":"publisher","award":["IP30EY025585"],"award-info":[{"award-number":["IP30EY025585"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background\/Objectives<\/jats:title>\n                <jats:p>Anti-VEGF treatment response in DMO has been measured by changes in the central subfield thickness (CST) and best visual acuity (BVA) outcomes at 3 months after initial treatment, termed early or limited early response (ER\/LER). This study correlates LER with 12-month BVA, CST, and retinal fluid volumes quantified by a machine learning algorithm on optical coherence tomography (OCT).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Subjects\/Methods<\/jats:title>\n                <jats:p>The study included treatment na\u00efve DMO patients \u2265 18 years with OCT scans at baseline (M0), M3, M6, and M12. The 220 patients were categorized as limited early responders (LER) if they had \u2264 10% CST reduction and\/or &lt; 5 ETDRS letter gain at M3. BVA, CST, and subretinal (SRF), intraretinal (IRF), and total retinal (TRF) fluid volumes quantified by a machine learning algorithm were compared between groups and across time.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>At M12, the anatomic LER (aLER), defined solely by CST, had significantly worse BVA and CST versus the anatomic ER (aER) group (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Retinal fluid M12 outcomes did not significantly vary between all LER and ER groups. No significant BVA, CST, TRF, and IRF variance across time for LER was found (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.1).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>BVA and CST M12 outcomes vary by aLER\/aER status indicating that CST may be a strong predictor of treatment outcomes, while retinal fluid volumes were not predicted by LER status.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41433-024-03172-4","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T18:16:10Z","timestamp":1718734570000},"page":"2805-2812","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Correlation of limited-early-response status with 12-month CST, BVA, and machine learning-quantified retinal fluid in diabetic macular oedema in routine clinical practice"],"prefix":"10.1038","volume":"38","author":[{"given":"Resya C.","family":"Sastry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6197-9476","authenticated-orcid":false,"given":"Scott W.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneesha","family":"Kalur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5859-8162","authenticated-orcid":false,"given":"Rishi P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,18]]},"reference":[{"key":"3172_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.survophthal.2008.10.001","volume":"54","author":"N Bhagat","year":"2009","unstructured":"Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular Edema: Pathogenesis and treatment. Surv Ophthalmol. 2009;54:1\u201332. https:\/\/doi.org\/10.1016\/j.survophthal.2008.10.001","journal-title":"Surv Ophthalmol"},{"key":"3172_CR2","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1001\/jamaophthalmol.2014.2854","volume":"132","author":"R Varma","year":"2014","unstructured":"Varma R, Bressler NM, Doan QV, Gleeson M, Danese M, Bower JK, et al. Prevalence of and risk factors for Diabetic macular edema in the United States. JAMA Ophthalmol. 2014;132:1334. https:\/\/doi.org\/10.1001\/jamaophthalmol.2014.2854","journal-title":"JAMA Ophthalmol"},{"key":"3172_CR3","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/S0161-6420(86)33650-9","volume":"93","author":"GH Bresnick","year":"1986","unstructured":"Bresnick GH. Diabetic macular edema: a review. Ophthalmology. 1986;93:989\u201397. https:\/\/doi.org\/10.1016\/S0161-6420(86)33650-9","journal-title":"Ophthalmology"},{"key":"3172_CR4","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.2337\/diacare.26.9.2653","volume":"26","author":"TA Ciulla","year":"2003","unstructured":"Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema. Diabetes Care. 2003;26:2653\u201364. https:\/\/doi.org\/10.2337\/diacare.26.9.2653","journal-title":"Diabetes Care"},{"key":"3172_CR5","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1007\/s00125-016-3974-8","volume":"59","author":"B Bahrami","year":"2016","unstructured":"Bahrami B, Zhu M, Hong T, Chang A. Diabetic macular oedema: pathophysiology, management challenges and treatment resistance. Diabetologia. 2016;59:1594\u2013608. https:\/\/doi.org\/10.1007\/s00125-016-3974-8","journal-title":"Diabetologia"},{"key":"3172_CR6","doi-asserted-by":"publisher","first-page":"100","DOI":"10.2174\/1573399810666140402123026","volume":"10","author":"P Romero-Aroca","year":"2014","unstructured":"Romero-Aroca P, Reyes-Torres J, Baget-Bernaldiz M, Blasco-Sune C. Laser treatment for diabetic macular edema in the 21st century. Curr Diabetes Rev. 2014;10:100\u201312. https:\/\/doi.org\/10.2174\/1573399810666140402123026","journal-title":"Curr Diabetes Rev"},{"key":"3172_CR7","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s11892-012-0281-8","volume":"12","author":"MW Stewart","year":"2012","unstructured":"Stewart MW. Corticosteroid use for Diabetic macular EDEMA: OLD fad or new trend? Curr Diabetes Rep. 2012;12:364\u201375. https:\/\/doi.org\/10.1007\/s11892-012-0281-8","journal-title":"Curr Diabetes Rep"},{"key":"3172_CR8","doi-asserted-by":"publisher","unstructured":"Stefanini FR, Badaro E, Falabella P, Koss M, Farah ME, Maia M. Anti-VEGF for the management of diabetic macular edema. J Immunol Res. 2014. https:\/\/doi.org\/10.1155\/2014\/632307","DOI":"10.1155\/2014\/632307"},{"key":"3172_CR9","first-page":"44","volume":"27","author":"D Yortson","year":"2014","unstructured":"Yortson D. Anti-VEGF drugs in the prevention of blindness. Community Eye Health J. 2014;27:44\u20136.","journal-title":"Community Eye Health J"},{"key":"3172_CR10","doi-asserted-by":"publisher","unstructured":"Boyer DS, Ehrlich JA, Sorof J, Hopkins JJ. Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab. 2013. https:\/\/doi.org\/10.1177\/2042018813512360","DOI":"10.1177\/2042018813512360"},{"key":"3172_CR11","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.oret.2017.1.0.014","volume":"2","author":"D Pieramici","year":"2018","unstructured":"Pieramici D, Singh RP, Gibson A, Saroj N, Vitti R, Berliner AJ, et al. Outcomes of diabetic macular edema eyes with limited early response in the VISTA and VIVID studies. Ophthalmol Retin. 2018;2:558\u201366. https:\/\/doi.org\/10.1016\/j.oret.2017.1.0.014","journal-title":"Ophthalmol Retin"},{"key":"3172_CR12","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3928\/23258160-20200326-02","volume":"51","author":"RP Singh","year":"2020","unstructured":"Singh RP, Piermaci DJ, Wang P-wen, Gune S. Long-term vision outcomes in patients with DME and a limited early visual response to Ranibizumab in RIDE and RISE. Ophthalmic Surg Lasers Imaging Retin. 2020;51:210\u20138. https:\/\/doi.org\/10.3928\/23258160-20200326-02","journal-title":"Ophthalmic Surg Lasers Imaging Retin"},{"key":"3172_CR13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/iae.0000000000002110","volume":"39","author":"PU Dugel","year":"2019","unstructured":"Dugel PU, Campbell JH, Kiss S, Loewenstein A, Shih V, Xu X, et al. Association between early anatomic response to anti\u2013vascular endothelial growth factor therapy and long-term outcome in diabetic macular edema. Retina. 2019;39:88\u201397. https:\/\/doi.org\/10.1097\/iae.0000000000002110","journal-title":"Retina"},{"key":"3172_CR14","doi-asserted-by":"publisher","unstructured":"Michl M, Fabianska M, Seeb\u00f6ck P, Sadeghipour A, Najeeb BH, Bogunovic H, et al. Automated quantification of macular fluid in retinal diseases and their response to anti-vegf therapy. Br J Ophthalmol. 2020. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-317416","DOI":"10.1136\/bjophthalmol-2020-317416"},{"key":"3172_CR15","doi-asserted-by":"publisher","first-page":"908","DOI":"10.3928\/23258160-20161004-03","volume":"47","author":"Y Itoh","year":"2016","unstructured":"Itoh Y, Petkovsek D, Kaiser PK, Singh RP, Ehlers JP. Optical coherence tomography features in diabetic macular edema and the impact on anti-vegf response. Ophthalmic Surg Lasers Imaging Retin. 2016;47:908\u201313. https:\/\/doi.org\/10.3928\/23258160-20161004-03","journal-title":"Ophthalmic Surg Lasers Imaging Retin"},{"key":"3172_CR16","unstructured":"Kaakour A, Song W, Kalur A, Iyer A, Muste J, Singh RP. Performance of an Artificial Intelligence model in retinal fluid quantification for patients with diabetic macular edema and retinal vein occlusions. Investig Ophthalmol Vis Sci: ARVO Annual Meeting Abstract. 2021."},{"key":"3172_CR17","doi-asserted-by":"crossref","unstructured":"Kalur A, Iyer AI, Muste JC, Talcott KE, Singh RP. Impact of retinal fluid in patients with diabetic macular edema with anti-VEGF in routine clinical practice. Can J Ophthalmol 2023;58:271\u20137.","DOI":"10.1016\/j.jcjo.2022.03.003"},{"key":"3172_CR18","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.ophtha.2016.04.005","volume":"123","author":"U Chakravarthy","year":"2016","unstructured":"Chakravarthy U, Goldenberg D, Young G, Havilio M, Rafaeli O, Benyamini G, et al. Automated identification of lesion activity in neovascular age-related macular degeneration. Ophthalmology. 2016;123:1731\u20136. https:\/\/doi.org\/10.1016\/j.ophtha.2016.04.005","journal-title":"Ophthalmology"},{"key":"3172_CR19","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.ophtha.2016.02.007","volume":"123","author":"DJ Pieramici","year":"2016","unstructured":"Pieramici DJ, Wang P, Ding B, Gune S. Visual and anatomic outcomes in patients with diabetic macular edema with limited initial anatomic response to ranibizumab in Ride and rise. Ophthalmology. 2016;123:1345\u201350. https:\/\/doi.org\/10.1016\/j.ophtha.2016.02.007","journal-title":"Ophthalmology"},{"key":"3172_CR20","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ajo.2021.06.030","volume":"232","author":"MR Starr","year":"2021","unstructured":"Starr MR, Salabati M, Mahmoudzadeh R, Patel LG, Ammar MJ, Hsu J, et al. Fluctuations in central subfield thickness associated with worse visual outcomes in patients with diabetic macular edema in clinical trial setting. Am J Ophthalmol. 2021;232:90\u20137. https:\/\/doi.org\/10.1016\/j.ajo.2021.06.030","journal-title":"Am J Ophthalmol"},{"key":"3172_CR21","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/jamaophthalmol.2018.6786","volume":"137","author":"SB Bressler","year":"2019","unstructured":"Bressler SB, Odia I, Maguire MG, Dhoot DS, Glassman AR, Jampol LM, et al. Factors associated with visual acuity and central subfield thickness changes when treating diabetic macular edema with anti-vascular endothelial growth factor therapy: an exploratory analysis of the Protocol T randomized clinical trial. JAMA Ophthalmol. 2019;137:382\u20139. https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.6786","journal-title":"JAMA Ophthalmol"},{"key":"3172_CR22","doi-asserted-by":"crossref","unstructured":"Ehlers JP, Uchida A, Hu M, Figueiredo N, Kaiser PK, Heier JS, et al. Higher-order assessment of OCT in diabetic macular Edema from the VISTA Study: Ellipsoid zone dynamics and the Retinal Fluid Index, Ophthalmol Retina. 2019;3:1056\u201366.","DOI":"10.1016\/j.oret.2019.06.010"},{"key":"3172_CR23","doi-asserted-by":"crossref","unstructured":"Ahuja S, Saxena S, Meyer CH, Gilhotra JS, Akduman L. Central subfield thickness and cube average thickness as bioimaging biomarkers for ellipsoid zone disruption in diabetic retinopathy. Int J Retina Vitreous. 2018;4:1\u20135.","DOI":"10.1186\/s40942-018-0144-9"},{"key":"3172_CR24","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.ophtha.2020.03.021","volume":"127","author":"AR Glassman","year":"2020","unstructured":"Glassman AR, Wells JA, Josic K, Josic K, Maguire MG, Antoszyk AN, et al. Five-year outcomes after initial AFLIBERCEPT, bevacizumab, or ranibizumab treatment for diabetic macular edema (Protocol T extension study). Ophthalmology. 2020;127:1201\u201310. https:\/\/doi.org\/10.1016\/j.ophtha.2020.03.021","journal-title":"Ophthalmology"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03172-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03172-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03172-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T07:06:54Z","timestamp":1727334414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03172-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,18]]},"references-count":24,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["3172"],"URL":"https:\/\/doi.org\/10.1038\/s41433-024-03172-4","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,18]]},"assertion":[{"value":"15 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Rishi P. Singh reports personal fees from Genentech\/Roche, personal fees from Alcon\/Novartis, and grants from Apellis and Graybug, personal fees from Zeiss, personal fees from Bausch + Lomb, personal fees from Regeneron Pharmaceuticals, Inc and personal fees from Gyroscope and Asceplix.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}